Drug or technology
6 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for tramadol hydrochloride REMS; establishes risk mitigation requirements but does not report clinical trial data or efficacy evidence.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for tramadol hydrochloride extended-release tablets; this is a regulatory action, not a clinical efficacy study.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for a Risk Evaluation and Mitigation Strategy (REMS) on an existing tramadol extended-release product; a regulatory action without clinical trial data.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for tramadol hydrochloride; describes a regulatory action, not a clinical trial or efficacy evidence.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for tramadol hydrochloride extended-release tablets; this is a regulatory action, not a clinical efficacy study.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of tramadol hydrochloride tablet formulation under REMS framework; establishes risk mitigation requirements but does not report clinical efficacy or comparative trial outcomes.